Amber Therapeutics successfully closed Series A funding of $100 million (£80 million) from leading healthcare and technology investors in the US and UK.
Software spinout founders and investors now have a valuable resource to expedite their scaling efforts with the launch of the latest USIT guide this week.
Everyone loves hearing The A-Day’s origin story. Helping out at the infamous ‘Jungle’ refugee camp in Calais, a group of Oxford University postgraduate students saw first-hand the widespread issues of malnutrition and dental disease among refugees.
Approximately half of the spinout companies created in Oxford involve software. In response to a recent government-commissioned review calling for specific terms for ventures exclusively focused on software, OUI's Dr Richard Auburn shares his views.
Rob McNeil, Oxford University's Migration Observatory, engages in consultancy work facilitated by OUI, supporting journalists and communicators in fostering informed and balanced discussions on migration.
Oxford University Innovation announces the much-anticipated relaunch of the Oxford Innovation Society (OIS). With an ambitious 12-month programme of events, OIS aims to fortify connections between Oxford’s companies, investors, industry partners and the vibrant Oxford entrepreneurial ecosystem.
This year, around 100,000 people in the UK will have a stroke. AI algorithms developed by Oxford University spinout Brainomix are ensuring that more of those patients will receive better care and better outcomes.
Oxford University Innovation (OUI) welcomes the Independent Review of University Spin-out companies, published today.
Charting a vibrant future for the Oxford Innovation Society (OIS), Louise Male and Andrea Stewart spark a call to action for a collective, co-created evolution of this historic network. Engage in shaping an innovation hub where useful collaborations, diverse engagements, and a novel digital interface drive the next wave of breakthroughs in Oxford's dynamic ecosystem.
Beacon Therapeutics, a pioneering new biotech company, has launched with a mission to restore and improve the vision of patients with retinal diseases. The company is one of the most ambitious spinouts the University has been involved in to date, starting out with an impressive £96 million ($118.5m) in funding, the biggest launch for any company including an Oxford spin-out programme.
